Arthur D. Levinson, the chief executive of the biotechnology company Genentech, is a scientist who worked his way up through the research department and says the favorite part of his week is attending the Wednesday meetings at which experimental drugs are discussed. While he has learned the financial side of Genentech, he concedes that he lacks the love of administrative detail to run a conventional pharmaceuticals giant. “I’d be an awful head of Big Pharma,” he said.
